Warning View the most recent version.

Archived Content

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please "contact us" to request a format other than those available.

1. Micheli A, Mugno E, Krogh V, et al. Cancer prevalence in European registry areas. Annals of Oncology 2002; 13: 840-65.

2. De Angelis R, Grande E, Inghelmann R, et al. Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 2007; 93: 392-7.

3. Capocaccia R, Colonna M, Corazziari I, et al.   Measuring cancer prevalence in Europe: the EUROPREVAL project. Annals of Oncology 2002; 13: 831-9.

4. Statistics Canada. Cancer Incidence in Canada. Ottawa: Minister of Industry, 2011. CANSIM table 103-0550 released September 27, 2011.

5. Statistics Canada. Cancer Survival Statistics. Ottawa: Minister of Industry, 2011. CANSIM table 103-1571 released February 22, 2011.

6. Ellison LF, Wilkins K. An update on cancer survival. Health Reports 2010; 21(3): 55-60.

7. Ellison LF, Pogany L, Mery LS.  Childhood and adolescent cancer survival:  A period analysis of data from the Canadian Cancer Registry. European Journal of Cancer 2007; 43: 1967-75.

8. Ellison LF, Wilkins K. Cancer prevalence in the Canadian population. Health Reports 2009; 20(1): 7-14.

9. Statistics Canada. Demographic Estimates Compendium 2010. Ottawa: Minister of Industry, 2010. CANSIM table 051-0001 released September 29, 2010.

10. Parkin DM, Chen VW, Ferlay J, et al. Comparability and Quality Control in Cancer Registration. International Agency for Research on Cancer (IARC) Technical Publications, No. 19. Lyon: IARC, 1994.

11. Fritz A, Percy C, Jack A, et al. , eds. International Classification of Diseases for Oncology, Third Edition. Geneva: World Health Organization, 2000.

12. Altekruse SF, Kosary CL, Krapcho M, et al. , eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, Maryland: National Cancer Institute. Based on November 2009 SEER data submission, posted to the SEER website, 2010. Available at:

13. Feldman AR, Kessler L, Myers MH, et al. The prevalence of cancer. Estimates based upon the Connecticut tumor registry. The New England Journal of Medicine 1986; 315: 1394-7.

14. Gail MH, Kessler L, Midthune D, et al. Two approaches for estimating disease prevalence from population-based registries of incidence and mortality. Biometrics 1999; 55: 1137-44.

15. Statistics Canada. Vital Statistics Compendium 1996 (Statistics Canada, Catalogue 84-214-XPE) Ottawa: Minister of Industry, 1999.

16. Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program. Version 3.4.3 – April 2010. Statistical Research and Applications Branch,National Cancer Institute, 2010. Available at:

17. Statistics Canada. Cancer Incidence in Canada. Ottawa: Minister of Industry, 2011. CANSIM table 103-0553 released September 27, 2011.

18. McDermott S, DesMeules M, Lewis R, et al. Cancer incidence among Canadian immigrants, 1980-1998: Results from a National Cohort Study. Journal of Immigrant and Minority Health 2011; 13(1): 15-26.

19. Dyer Z, Peltekian K, Veldhuyzen van Zanten S. Review article: the changing epidemiology of hepatocellular carcinoma in Canada.  Alimentary Pharmacology and Therapeutics 2005; 22: 17-22.

20. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. Journal of Clinical Oncology 2009; 27: 1485-91.

21. Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. Canadian Medical Association Journal 2007; 177: 1357-61.

22. Sprague BL, Warren Andersen S, Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes and Control 2008; 19(6): 585-93.

23. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiology, Biomarkers and Prevention 2009; 18: 784-91.

24. American Cancer Society.  Anal Cancer. Available at:  Accessed May 10, 2011.

25. Chiao EY, Krown SE, Stier EA, et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. Journal of Acquired Immune Deficiency Syndromes 2005; 40(4): 451-5.

26. Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. British Journal of Urology International 2011;doi: 10.1111/j.1464-410X.2011.10197.x.

27. Fradet Y, Klotz L, Trachtenberg J, et al. The burden of prostate cancer in Canada. Canadian Urological Association Journal 2009; 3(3 Suppl. 2): S92-100.

28. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto: Canadian Cancer Society, 2011.

29. Stephens M, Siroonian J. Smoking prevalence, quit attempts and successes. Health Reports 1998; 9(4): 31-7.

30. Liu S, Semenciw R, Mao Y. Cervical cancer:  the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women.  Canadian Medical AssociationJournal 2001; 164(8): 1151-2.

31. Brisson J, Major D, Pelletier. Evaluation of the Completeness of the fichier des tumeurs du Québec. Quebec: Institut national de la santé publique du Québec, 2003.

32. Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registries data. Statistics in Medicine 1997; 16: 425-40.

33. Coldman AJ, McBride ML, Braun T. Calculating the prevalence of cancer. Statistics in Medicine 1992; 11: 1579-89.